Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC),...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3271/10/1/15 |
| _version_ | 1797445198175797248 |
|---|---|
| author | Hisham F. Bahmad Timothy Demus Maya M. Moubarak Darine Daher Juan Carlos Alvarez Moreno Francesca Polit Olga Lopez Ali Merhe Wassim Abou-Kheir Alan M. Nieder Robert Poppiti Yumna Omarzai |
| author_facet | Hisham F. Bahmad Timothy Demus Maya M. Moubarak Darine Daher Juan Carlos Alvarez Moreno Francesca Polit Olga Lopez Ali Merhe Wassim Abou-Kheir Alan M. Nieder Robert Poppiti Yumna Omarzai |
| author_sort | Hisham F. Bahmad |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical’s mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An alternative way to treat PCa is by repurposing of existing drugs that were initially intended for other conditions. By extrapolating the effects of previously approved drugs to the intracellular processes of PCa, treatment options will expand. In addition, drug repurposing is cost-effective and efficient because it utilizes drugs that have already demonstrated safety and efficacy. This review catalogues the drugs that can be repurposed for PCa in preclinical studies as well as clinical trials. |
| first_indexed | 2024-03-09T13:23:17Z |
| format | Article |
| id | doaj.art-5b47bc17683a43daadeada1edabf310a |
| institution | Directory Open Access Journal |
| issn | 2076-3271 |
| language | English |
| last_indexed | 2024-03-09T13:23:17Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medical Sciences |
| spelling | doaj.art-5b47bc17683a43daadeada1edabf310a2023-11-30T21:27:39ZengMDPI AGMedical Sciences2076-32712022-02-011011510.3390/medsci10010015Overcoming Drug Resistance in Advanced Prostate Cancer by Drug RepurposingHisham F. Bahmad0Timothy Demus1Maya M. Moubarak2Darine Daher3Juan Carlos Alvarez Moreno4Francesca Polit5Olga Lopez6Ali Merhe7Wassim Abou-Kheir8Alan M. Nieder9Robert Poppiti10Yumna Omarzai11Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USADivision of Urology, Columbia University, Mount Sinai Medical Center, Miami Beach, FL 33140, USADepartment of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, LebanonFaculty of Medicine, American University of Beirut, Beirut 1107-2020, LebanonArkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAArkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAHerbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USADepartment of Urology, Jackson Memorial Hospital, University of Miami, Leonard M. Miller School of Medicine, Miami, FL 33136, USADepartment of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, LebanonDivision of Urology, Columbia University, Mount Sinai Medical Center, Miami Beach, FL 33140, USAArkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAArkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USAProstate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical’s mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An alternative way to treat PCa is by repurposing of existing drugs that were initially intended for other conditions. By extrapolating the effects of previously approved drugs to the intracellular processes of PCa, treatment options will expand. In addition, drug repurposing is cost-effective and efficient because it utilizes drugs that have already demonstrated safety and efficacy. This review catalogues the drugs that can be repurposed for PCa in preclinical studies as well as clinical trials.https://www.mdpi.com/2076-3271/10/1/15drug repurposingandrogen-deprivation therapyprostate cancerCRPC |
| spellingShingle | Hisham F. Bahmad Timothy Demus Maya M. Moubarak Darine Daher Juan Carlos Alvarez Moreno Francesca Polit Olga Lopez Ali Merhe Wassim Abou-Kheir Alan M. Nieder Robert Poppiti Yumna Omarzai Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing Medical Sciences drug repurposing androgen-deprivation therapy prostate cancer CRPC |
| title | Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing |
| title_full | Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing |
| title_fullStr | Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing |
| title_full_unstemmed | Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing |
| title_short | Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing |
| title_sort | overcoming drug resistance in advanced prostate cancer by drug repurposing |
| topic | drug repurposing androgen-deprivation therapy prostate cancer CRPC |
| url | https://www.mdpi.com/2076-3271/10/1/15 |
| work_keys_str_mv | AT hishamfbahmad overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT timothydemus overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT mayammoubarak overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT darinedaher overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT juancarlosalvarezmoreno overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT francescapolit overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT olgalopez overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT alimerhe overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT wassimaboukheir overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT alanmnieder overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT robertpoppiti overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing AT yumnaomarzai overcomingdrugresistanceinadvancedprostatecancerbydrugrepurposing |